All news

Cantor Fitzgerald reiterates Atrium Therapeutics stock Overweight

Alpha Vantage · Investing.com · · AI-summarised by FinFlash

Cantor Fitzgerald reiterated an Overweight rating and $25.00 price target on Atrium Therapeutics (NASDAQ:RNA) after a $50 million private placement expected to extend the company's cash runway through 2028. The firm argues the market is significantly undervaluing the stock, which trades at roughly negative

Read original source

RNA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.